CDK5 and early-onset autosomal dominant Alzheimer disease: CRMP2 serves as a physiological target for the kinases glycogen synthase kinase-3β (GSK-3β) and cyclin-dependent kinase 5 (Cdk5), both of which show heightened activity in Alzheimer’s disease [37,38,39,40].